Gene-silencing siRNA has shown great promise for the treatment of genetic diseases,cancers,and viral infections,but its therapeutic value has been hindered by the lack of an efficient and safe in vivo delivery system ...Gene-silencing siRNA has shown great promise for the treatment of genetic diseases,cancers,and viral infections,but its therapeutic value has been hindered by the lack of an efficient and safe in vivo delivery system to target specific cells.The motor pRNA of phi29 has a strong tendency to form dimers,trimers and hexamers by interaction of interlocking right and left hand loops.This unique feature makes pRNA an ideal vector for the delivery of multiple therapeutic RNAs.Toxicity of pRNA was detected by transfection of 8 pRNA in HeLa cells.A pRNA-based vector was designed to carry siRNAs to inhibit GFP or HBV surface gene expression.Silence effects on siRNA against expression of GFP or HBV surface gene were detected in HeLa cells.Viral replicative intermediates were detected by Southern blotting.The results of toxicity study showed there was no toxicity of pRNA to cultured monolayer cells.The siRNA connected with pRNA can inhibit GFP or HBV surface gene expression in HeLa cells and inhibit HBV replication in HepG2 cells.These data suggest that pRNA can be used as a vector for imparting stability to siRNA in vitro.展开更多
目的:预测人宫颈癌基因(human cervical cancer oncogene,HCCR)蛋白的二级结构,B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位.方法:综合分析二级结构、亲水性、柔韧性、表面可及性与抗原性指数,预测HCCR蛋白的B细胞抗原表位;利用BIMAS,...目的:预测人宫颈癌基因(human cervical cancer oncogene,HCCR)蛋白的二级结构,B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位.方法:综合分析二级结构、亲水性、柔韧性、表面可及性与抗原性指数,预测HCCR蛋白的B细胞抗原表位;利用BIMAS,SYFPEITHI和NetCTL方法预测分析其HLA-A*0201限制性CTL表位,运用NetCTL方法对HLA-A的其他等位基因和HLA-B限制性CTL表位进行预测分析.结果:HCCR蛋白的二级结构主要由α-螺旋结构组成,B细胞优势表位位于N端第41～53,216～228,310～325和355～360区段;预测得到5个HLA-A*0201限制性CTL优势表位分别为YLVFLLMYL(152～160),YLFPRQLLI(159～167),LLLHNVVLL(343～351),CLFLGIISI(138～146)和SIPPFA-NYL(145～153),HCCR蛋白HLA-A,B限制CTL表位主要位于胞外区.结论:应用多参数预测HCCR蛋白B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位,为进一步实验鉴定其表位进而制备单克隆抗体和基于HCCR抗原的肿瘤免疫学治疗奠定了基础.展开更多
文摘Gene-silencing siRNA has shown great promise for the treatment of genetic diseases,cancers,and viral infections,but its therapeutic value has been hindered by the lack of an efficient and safe in vivo delivery system to target specific cells.The motor pRNA of phi29 has a strong tendency to form dimers,trimers and hexamers by interaction of interlocking right and left hand loops.This unique feature makes pRNA an ideal vector for the delivery of multiple therapeutic RNAs.Toxicity of pRNA was detected by transfection of 8 pRNA in HeLa cells.A pRNA-based vector was designed to carry siRNAs to inhibit GFP or HBV surface gene expression.Silence effects on siRNA against expression of GFP or HBV surface gene were detected in HeLa cells.Viral replicative intermediates were detected by Southern blotting.The results of toxicity study showed there was no toxicity of pRNA to cultured monolayer cells.The siRNA connected with pRNA can inhibit GFP or HBV surface gene expression in HeLa cells and inhibit HBV replication in HepG2 cells.These data suggest that pRNA can be used as a vector for imparting stability to siRNA in vitro.
文摘目的:预测人宫颈癌基因(human cervical cancer oncogene,HCCR)蛋白的二级结构,B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位.方法:综合分析二级结构、亲水性、柔韧性、表面可及性与抗原性指数,预测HCCR蛋白的B细胞抗原表位;利用BIMAS,SYFPEITHI和NetCTL方法预测分析其HLA-A*0201限制性CTL表位,运用NetCTL方法对HLA-A的其他等位基因和HLA-B限制性CTL表位进行预测分析.结果:HCCR蛋白的二级结构主要由α-螺旋结构组成,B细胞优势表位位于N端第41～53,216～228,310～325和355～360区段;预测得到5个HLA-A*0201限制性CTL优势表位分别为YLVFLLMYL(152～160),YLFPRQLLI(159～167),LLLHNVVLL(343～351),CLFLGIISI(138～146)和SIPPFA-NYL(145～153),HCCR蛋白HLA-A,B限制CTL表位主要位于胞外区.结论:应用多参数预测HCCR蛋白B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位,为进一步实验鉴定其表位进而制备单克隆抗体和基于HCCR抗原的肿瘤免疫学治疗奠定了基础.
